| Name | Title | Contact Details |
|---|
Blueprint Medicines is developing a new generation of highly selective and potent kinase therapies to dramatically improve the lives of patients with genomically defined diseases. Our approach is rooted in a deep understanding of the genetic blueprint of cancer and other diseases driven by the abnormal activation of kinases. Our ability to identify novel drivers of disease, coupled with our proprietary library of novel and diverse chemical compounds, uniquely enables us to craft kinase therapies against new and difficult-to-drug targets. We are boldly advancing a deep pipeline of highly targeted therapies against previously unaddressed drivers of disease. By focusing on genomically defined subsets of patients, we believe we can identify the people most likely to respond to our therapies, resulting in a more efficient clinical development path with a greater likelihood of success and better outcomes for patients. We see a substantial opportunity in kinase drug discovery and development to deliver breakthrough medicines that allow patients to live longer with better quality of life and prevent recurrences of disease. Kinases are involved in many hallmarks of tumor biology and are proven cancer drug targets. Currently approved drugs focus on less than 5 percent of known kinases, and the function of most kinases is unknown. Led by a team of industry innovators with a track record of bringing life-changing drugs to market, we believe Blueprint Medicines has the experience and expertise to deliver on the tremendous untapped potential of kinase therapies to improve patients’ lives. We don’t think in small steps. We think in giant leaps. We are driven by the pursuit of new ideas, new innovations, and new ways of thinking.
UConn Health is a vibrant, integrated academic medical center that is entering an era of unprecedented growth in all three areas of its mission: academics, research, and clinical care. UConn Health is at the center of Bioscience Connecticut, a bold plan introduced by Connecticut Governor Dannel P. Malloy and approved by the Connecticut General Assembly in 2011. The plan will strengthen Connecticut`s position as a national and global leader for bioscience innovation and improve access to quality health care for Connecticut citizens for generations to come. Based in Farmington, Connecticut – a popular suburb of the state`s capitol of Hartford – UConn Health is home to the School of Medicine, School of Dental Medicine, John Dempsey Hospital, UConn Medical Group, UConn Health Partners, University Dentists and a thriving research enterprise. With approximately 5,000 employees, UConn Health is a major economic driver in the region, generating nearly $1 billion annually in gross state product. It is closely linked with the University of Connecticut`s main campus in Storrs through multiple, cross-campus academic projects.
Medical Claims Assistance is a Huntington, WV-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Masimo Corporation is a global medical technology company that develops, manufactures and markets non-invasive patient monitoring products.
Unicity International is a Orem, UT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.